November 15, 2015 10:00 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) announced Saturday, new data from AbbVie's ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets), taken with or without ribavirin (RBV), in adult patients with genotype 1a (GT1a) or genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection.1 Interim data show that 95 percent (n=586/615) of patients in the TOPAZ-II trial achieved a sustained virological response at 12 weeks post-treatment after 12 or 24 weeks of treatment, a secondary endpoint for the study.1 These data were presented today at The Liver Meeting® 2015, the Annual Meeting of the American
See full press release
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.